MANNKIND CORP Cash and Cash Equivalents, Period Increase (Decrease)
MANNKIND CORP (MNKD) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$2.80 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2017-11-07
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$23.29M.
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$4.59M, a 112.73% decline year-over-year.
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $25.08M.
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$12.63M, a 148.32% decline year-over-year.
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$36.18M.
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$61.77M, a 223.41% decline from fiscal 2014.
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for fiscal 2014 was $50.05M, a 459.23% increase from fiscal 2013.
- MANNKIND CORP cash and cash equivalents, period increase (decrease) for fiscal 2013 was $8.95M, a 84.87% decline from fiscal 2012.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 244 month | Cash and Cash Equivalents, Period Increase (Decrease) 247 month | Cash and Cash Equivalents, Period Increase (Decrease) 250 month | Cash and Cash Equivalents, Period Increase (Decrease) 253 month | Cash and Cash Equivalents, Period Increase (Decrease) 256 month | Cash and Cash Equivalents, Period Increase (Decrease) 259 month | Cash and Cash Equivalents, Period Increase (Decrease) 263 month | Cash and Cash Equivalents, Period Increase (Decrease) 265 month | Cash and Cash Equivalents, Period Increase (Decrease) 268 month | Cash and Cash Equivalents, Period Increase (Decrease) 271 month | Cash and Cash Equivalents, Period Increase (Decrease) 275 month | Cash and Cash Equivalents, Period Increase (Decrease) 277 month | Cash and Cash Equivalents, Period Increase (Decrease) 280 month | Cash and Cash Equivalents, Period Increase (Decrease) 283 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-09-30 | -$23.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$27.89M derived: sum of 2 quarters · filed 2017-11-07 | -$2.80M 10-Q · filed 2017-11-07 | -$15.44M derived: sum of 4 quarters · filed 2017-11-07 | ||||||||||||||
| 2017-06-30 | -$4.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $20.49M 10-Q · filed 2017-08-07 | $7.85M derived: sum of 3 quarters · filed 2017-08-07 | -$20.35M derived: sum of 4 quarters · filed 2017-11-07 | ||||||||||||||
| 2017-03-31 | $25.08M 10-Q · filed 2017-05-10 | $12.45M derived: sum of 2 quarters · filed 2017-05-10 | -$15.76M derived: sum of 3 quarters · filed 2017-11-07 | $20.32M derived: sum of 4 quarters · filed 2017-11-07 | ||||||||||||||
| 2016-12-31 | -$12.63M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$40.84M derived: sum of 2 quarters · filed 2017-11-07 | -$4.76M derived: sum of 3 quarters · filed 2017-11-07 | -$36.18M 10-K · filed 2017-03-16 | ||||||||||||||
| 2016-09-30 | -$28.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $7.88M derived: sum of 2 quarters · filed 2017-11-07 | -$23.54M 10-Q · filed 2017-11-07 | $2.60M derived: sum of 4 quarters · filed 2017-11-07 | ||||||||||||||
| 2016-06-30 | $36.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $4.66M 10-Q · filed 2017-08-07 | $30.80M derived: sum of 3 quarters · filed 2017-08-07 | -$43.45M derived: sum of 4 quarters · filed 2017-08-07 | ||||||||||||||
| 2016-03-31 | -$31.42M 10-Q · filed 2017-05-10 | -$5.28M derived: sum of 2 quarters · filed 2017-05-10 | -$79.53M derived: sum of 3 quarters · filed 2017-05-10 | -$93.19M derived: sum of 4 quarters · filed 2017-05-10 | ||||||||||||||
| 2015-12-31 | $26.15M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$48.11M derived: sum of 2 quarters · filed 2017-03-16 | -$61.77M derived: sum of 3 quarters · filed 2017-03-16 | -$61.77M 10-K · filed 2017-03-16 | ||||||||||||||
| 2015-09-30 | -$74.26M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2016-11-09 | -$87.92M derived: sum of 2 quarters · filed 2016-11-09 | -$87.91M 10-Q · filed 2016-11-09 | -$139.54M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||
| 2015-06-30 | -$13.66M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | -$13.65M 10-Q/A · filed 2016-08-10 | -$65.28M derived: sum of 3 quarters · filed 2017-03-16 | $65.97M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||
| 2015-03-31 | $3.00K 10-Q · filed 2016-05-09 | -$51.62M derived: sum of 2 quarters · filed 2017-03-16 | $79.63M derived: sum of 3 quarters · filed 2017-03-16 | $85.08M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||
| 2014-12-31 | -$51.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $79.63M derived: sum of 2 quarters · filed 2017-03-16 | $85.08M derived: sum of 3 quarters · filed 2017-03-16 | $50.05M 10-K · filed 2017-03-16 | ||||||||||||||
| 2014-09-30 | $131.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $136.71M derived: sum of 2 quarters · filed 2015-11-09 | $101.67M 10-Q · filed 2015-11-09 | $78.66M derived: sum of 4 quarters · filed 2016-03-15 | $172.47M 10-Q · filed 2014-11-10 | |||||||||||||
| 2014-06-30 | $5.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$29.58M 10-Q · filed 2015-08-10 | -$52.59M derived: sum of 3 quarters · filed 2016-03-15 | $12.69M derived: sum of 4 quarters · filed 2016-03-15 | $41.21M 10-Q · filed 2014-08-11 | |||||||||||||
| 2014-03-31 | -$35.03M 10-Q · filed 2015-05-11 | -$58.04M derived: sum of 2 quarters · filed 2016-03-15 | $7.23M derived: sum of 3 quarters · filed 2016-03-15 | $7.75M derived: sum of 4 quarters · filed 2016-03-15 | $35.76M 10-Q · filed 2014-05-12 | |||||||||||||
| 2013-12-31 | -$23.01M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $42.26M derived: sum of 2 quarters · filed 2016-03-15 | $42.78M derived: sum of 3 quarters · filed 2016-03-15 | $8.95M 10-K · filed 2016-03-15 | $70.79M 10-K · filed 2014-03-03 | |||||||||||||
| 2013-09-30 | $65.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $65.80M derived: sum of 2 quarters · filed 2014-11-10 | $31.96M 10-Q · filed 2014-11-10 | $92.04M derived: sum of 4 quarters · filed 2015-03-02 | $93.80M 10-Q · filed 2013-11-12 | |||||||||||||
| 2013-06-30 | $524.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$33.31M 10-Q · filed 2014-08-11 | $26.76M derived: sum of 3 quarters · filed 2015-03-02 | -$3.11M derived: sum of 4 quarters · filed 2015-03-02 | $28.53M 10-Q · filed 2013-08-09 | |||||||||||||
| 2013-03-31 | -$33.84M 10-Q · filed 2014-05-12 | $26.24M derived: sum of 2 quarters · filed 2015-03-02 | -$3.63M derived: sum of 3 quarters · filed 2015-03-02 | -$28.35M derived: sum of 4 quarters · filed 2015-03-02 | $28.00M 10-Q · filed 2013-05-10 | |||||||||||||
| 2012-12-31 | $60.08M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $30.20M derived: sum of 2 quarters · filed 2015-03-02 | $5.49M derived: sum of 3 quarters · filed 2015-03-02 | $59.16M 10-K · filed 2015-03-02 | $61.84M 10-K · filed 2013-03-18 | |||||||||||||
| 2012-09-30 | -$29.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$54.59M derived: sum of 2 quarters · filed 2013-11-12 | -$916.00K 10-Q · filed 2013-11-12 | -$21.02M derived: sum of 4 quarters · filed 2014-03-03 | $1.76M 10-Q · filed 2012-11-09 | |||||||||||||
| 2012-06-30 | -$24.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $28.96M 10-Q · filed 2013-08-09 | $8.85M derived: sum of 3 quarters · filed 2014-03-03 | $6.87M derived: sum of 4 quarters · filed 2014-03-03 | $31.64M 10-Q · filed 2012-08-09 | |||||||||||||
| 2012-03-31 | $53.67M 10-Q · filed 2013-05-10 | $33.57M derived: sum of 2 quarters · filed 2014-03-03 | $31.59M derived: sum of 3 quarters · filed 2014-03-03 | $9.44M derived: sum of 4 quarters · filed 2014-03-03 | $56.35M 10-Q · filed 2012-05-10 | |||||||||||||
| 2011-12-31 | -$20.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$22.09M derived: sum of 2 quarters · filed 2014-03-03 | -$44.23M derived: sum of 3 quarters · filed 2014-03-03 | -$63.38M 10-K · filed 2014-03-03 | $2.68M 10-K · filed 2012-03-15 | |||||||||||||
| 2011-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$24.13M derived: sum of 2 quarters · filed 2012-11-09 | -$43.27M 10-Q · filed 2012-11-09 | -$75.14M derived: sum of 4 quarters · filed 2013-03-18 | $22.79M 10-Q · filed 2011-11-04 | |||||||||||||
| 2011-06-30 | -$22.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$41.29M 10-Q · filed 2012-08-09 | -$73.16M derived: sum of 3 quarters · filed 2013-03-18 | -$3.59M derived: sum of 4 quarters · filed 2013-03-18 | $24.77M 10-Q · filed 2011-08-04 | |||||||||||||
| 2011-03-31 | -$19.15M 10-Q · filed 2012-05-10 | -$51.02M derived: sum of 2 quarters · filed 2013-03-18 | $18.55M derived: sum of 3 quarters · filed 2013-03-18 | |||||||||||||||
| 2010-12-31 | -$31.87M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $37.70M derived: sum of 2 quarters · filed 2013-03-18 | $36.04M 10-K · filed 2013-03-18 | |||||||||||||||
| 2010-09-30 | $69.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $67.91M 10-Q · filed 2011-11-04 | ||||||||||||||||
| 2010-06-30 | -$1.66M 10-Q · filed 2011-08-04 | |||||||||||||||||
| 2009-12-31 | $2.37M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |